Mandy Fraessdorf

Ingelheim Am Rhein, RP, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Journal: Hepatology (Baltimore, Md.)
Published: December 17, 2025

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Journal: Hepatology (Baltimore, Md.)
Published: December 17, 2025

Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification.

Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification.

Journal: Hepatology communications
Published: October 23, 2025

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

Journal: The New England journal of medicine
Published: June 07, 2024

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Journal: Journal of hepatology
Published: April 25, 2024

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.

Journal: JAMA neurology
Published: September 04, 2019

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.

Journal: European heart journal
Published: August 20, 2019

Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.

Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
Published: September 05, 2018

Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis.

Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis.

Journal: International journal of stroke : official journal of the International Stroke Society
Published: May 19, 2018

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.

Journal: Journal of the American College of Cardiology
Published: February 21, 2018

Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.

Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.

Journal: Journal of thrombosis and haemostasis : JTH
Published: January 09, 2018

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.

Journal: Thrombosis and haemostasis
Published: March 13, 2017
Showing 1-12 of 24

Last Updated: 09/26/2026